Q4 2025 Anika Therapeutics Inc Earnings Call Transcript

Feb 26, 2026 / 01:30 PM GMT

Release Date Price: $12.79 (+16.91%)

Transcript 10-K8-K

Key Points

Positve

Anika Therapeutics Inc (ANIK) achieved a 22% growth in commercial channel revenue in Q4 2025, driven by strong international execution and continued momentum in their Integrity product.
The international OA pain management portfolio delivered a 28% growth in Q4, showcasing strong market share gains for Monovisc and Singal across several regions.
Integrity procedures and revenue more than doubled in 2025, marking its seventh consecutive quarter of sequential growth.
The company improved its GAAP gross margin to 63% in Q4 2025, up from 56% in the prior year, due to higher revenue from international OA pain sales and improved manufacturing productivity.
Anika Therapeutics Inc (ANIK) generated $11.2 million in operating cash flow for 2025, an improvement over the $5.4 million generated in 2024, driven by efficient working capital management and lower expenses.

Negative

OEM revenue declined by 12% in Q4 and 17% for the full year 2025, primarily due to a challenging US OA pain management pricing environment.
The company received a deficiency letter from the FDA related to CMC and clinical data for Hyalofast, indicating potential regulatory hurdles.
Non-orthopedic revenue declined in Q4 2025, reflecting lower demand for legacy products.
GAAP gross margin for the full year 2025 was 57%, down from 63% in 2024, due to product mix and higher manufacturing costs.
Total operating expenses for 2025 were $74.9 million, reflecting the need for continued cost discipline despite a reduction from the previous year.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ANIK.OQ - Anika Therapeutics Inc
Q4 2025 Anika Therapeutics Inc Earnings Call
Feb 26, 2026 / 01:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning ladies and gentlemen, and welcome to Anika's 4th quarter and year-end earnings conference call. At this time, all lines are in a lesson-only mode. Following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press 0 for the operator. This call is being recorded on Thursday, February 26, 2026. I would now like to turn the call over to Matt Hall, executive Director, Corporate Development and Investor relations. Please proceed.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Good

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by FactSet. Analyst estimates data is sourced from both Refinitiv and FactSet, with priority given to Refinitiv data. Data is updated daily.